Belgrade, Serbia – 17 May 2025. A pharmaceutically produced cannabidiol formulation had a good overall safety profile, including cardiac safety, according to research presented today at Heart Failure 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Currently, there are limited treatment options for inflammatory conditions of the heart, such as myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane surrounding the heart). Cannabidiol – which lacks the psychotropic effects of cannabis – has been shown to inhibit activation of the inflammasome pathway,2 an intracellular process known to be involved in the development and progression of myocarditis, pericarditis and heart failure.
Explaining the rationale for the current trial, Co-Principal Investigator, Dr. Leslie Cooper from the Mayo Clinic, Jacksonville, Florida, USA, said: “We knew that patients with cardiovascular disease (CVD) or CVD risk factors who were hospitalised for COVID-19 infection may be at high risk of cardiac inflammation. We conducted a placebo-controlled trial of an oral pharmaceutically manufactured (GMP) cannabidiol formulation to assess its efficacy and safety. The pandemic ended before we had recruited sufficient participants to analyse whether GMP-cannabidiol had a positive effect on the primary efficacy endpoint but we thought that the lack of safety signals was important data to share.”
This prospective trial included adult patients with a prior history of CVD and/or at least one major risk factor for CVD who had been hospitalised for non-critical COVID-19 infection. Participants were randomised to either GMP-cannabidiol titrated up to 7.5 mg/kg twice daily (or maximum tolerated dose) or placebo. The primary safety endpoint was the number of serious adverse events (SAEs) and adverse events (AEs) during the 60 days following randomisation.
The trial was terminated early due to a lack of eligible patients with COVID-19 to support full recruitment. The recruited safety population included 89 patients (mean age of 61 years; 43% female): 45 patients received GMP-cannabidiol and 44 received placebo.
Overall safety was similar between the groups. The frequency of investigator-assessed treatment-related AEs was 24.4% with GMP-cannabidiol and 22.7% with placebo. The frequency of SAEs was 11.1% with GMP-cannabidiol and 9.1% with placebo. There were 0 deaths in the GMP-cannabidiol group and 2 deaths in the placebo group, both due to respiratory failure.
There were no significant differences between groups in the most common AEs of gastrointestinal disorders (GMP-cannabidiol: 22.2%; placebo: 20.5%); nervous system disorders (GMP-cannabidiol: 17.8%, placebo: 18.2%); and respiratory, thoracic and mediastinal disorders (GMP-cannabidiol: 11.1%, placebo: 9.1%).
Of note, the cardiovascular safety profile of GMP-cannabidiol appeared similar to that of placebo. Cardiac disorders were reported in 4 patients (9%) in both the GMP-cannabidiol group and the placebo group. One patient (2%) in the GMP-cannabidiol group developed mild QTc prolongation detected by electrocardiogram (ECG). However, overall, changes in ECG measurements were minimal, with similar mean QTc values from baseline to day 28 in the GMP-cannabidiol group (425 msec and 418 msec, respectively) and in the placebo group (418 msec and 419 msec, respectively).
Summarising the findings, Dr. Cooper said: “GMP-cannabidiol was well tolerated overall and most importantly, the rate of cardiac side effects was low and similar compared with placebo. These safety data are encouraging as two larger trials assessing efficacy and safety are underway with GMP-cannabidiol. The phase II ARCHER trial3 in patients with acute myocarditis is expected to report later in 2025, while results from the phase III MAVERIC trial4 in patients with recurrent pericarditis are expected in 2026.”
ENDS
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow us on X @ESCardioNews
Funding: The trial was funded by Cardiol Therapeutics Inc.
Disclosures: Dr. Cooper serves as a consultant to Cardiol Therapeutics Inc.
References and notes:
1‘Cardiac safety of pharmaceutically manufactured cannabidiol in patients at increased cardiovascular risk’ will be presented during ePosters in myocardial disease (1) on 17 May at 10:46 CET on ePosters screen 13 in the Research Gateway.
2Martinez Naya N, Kelly J, Corna G, et al. Molecular and cellular mechanisms of action of cannabidiol. Molecules. 2023;28:5980.
3McNamara D, Cooper LT, Arbel A, et al. Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: Rationale & design of the ARCHER trial. ESC Heart Fail. 2024;11:3416–3424. NCT05180240.
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
About Heart Failure 2025
Heart Failure is the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). #HeartFailure2025
About the Heart Failure Association
The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Information for journalists about registration for Heart Failure 2025
Heart Failure 2025 takes place from 17 to 20 May at the Sava Centar, Belgrade, Serbia and online. Explore the scientific programme
-
Free registration applies to accredited press.
-
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
-
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
-
The ESC Press Office decision is final regarding all press registration requests.